{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:32:23Z","timestamp":1785256343537,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpba.2026.117495","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:49:51Z","timestamp":1775231391000},"page":"117495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Strategic characterization of active pharmaceutical ingredients co-eluting impurities: Identification, enrichment and structural elucidation of an oxidized impurity from mobocertinib drug substance"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-3671","authenticated-orcid":false,"given":"Yumin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-5384","authenticated-orcid":false,"given":"Ruiqiong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7928-1129","authenticated-orcid":false,"given":"Guanghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6253-5435","authenticated-orcid":false,"given":"Kazunobu","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6699","authenticated-orcid":false,"given":"Mark J.","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-8548","authenticated-orcid":false,"given":"Webster L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-6353","authenticated-orcid":false,"given":"Mark T.","family":"Zell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2026.117495_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jpba.2006.11.004","article-title":"Impurity profile tracking for active pharmaceutical ingredients: case reports","volume":"44","author":"Zhou","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"21","key":"10.1016\/j.jpba.2026.117495_bib2","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jssc.201800623","article-title":"Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin","volume":"41","author":"Huang","year":"2018","journal-title":"J. Sep Sci."},{"issue":"2","key":"10.1016\/j.jpba.2026.117495_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpba.2004.05.012","article-title":"Identification of low-level degradants from low dose tablets","volume":"36","author":"Blanchard","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.jpba.2026.117495_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jms.1184","article-title":"Applications of LC\/MS in structure identifications of small molecules and proteins in drug discovery","volume":"42","author":"Chen","year":"2007","journal-title":"J. Mass Spectrom."},{"issue":"3","key":"10.1016\/j.jpba.2026.117495_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/mas.21858","article-title":"What is the role of current mass spectrometry in pharmaceutical analysis?","volume":"43","author":"Khalikova","year":"2024","journal-title":"Mass Spectrom. Rev."},{"issue":"1","key":"10.1016\/j.jpba.2026.117495_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.analchem.8b04841","article-title":"Recent developments in two-dimensional liquid chromatography: fundamental improvements for practical applications","volume":"91","author":"Pirok","year":"2019","journal-title":"Anal. Chem."},{"issue":"18","key":"10.1016\/j.jpba.2026.117495_bib7","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/jssc.201300493","article-title":"Analysis of pharmaceutical impurities using multi-heartcutting 2D LC coupled with UV-charged aerosol MS detection","volume":"36","author":"Zhang","year":"2013","journal-title":"J. Sep Sci."},{"key":"10.1016\/j.jpba.2026.117495_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2025.344431","article-title":"Identification of oligonucleotide drug impurities using heart-cutting two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS\/MS)","volume":"1371","author":"Zhou","year":"2025","journal-title":"Anal. Chim. Acta"},{"issue":"9","key":"10.1016\/j.jpba.2026.117495_bib9","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1021\/acs.analchem.4c06662","article-title":"Trends in pharmaceutical analysis: the evolving role of liquid chromatography","volume":"97","author":"D'Atri","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117495_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chroma.2017.08.070","article-title":"Comprehensive two dimensional liquid chromatography as analytical strategy for pharmaceutical analysis","volume":"1536","author":"Iguiniz","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117495_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpba.2016.11.012","article-title":"2D-LC as an on-line desalting tool allowing peptide identification directly from MS unfriendly HPLC methods","volume":"137","author":"Luo","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"8","key":"10.1016\/j.jpba.2026.117495_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.70238","article-title":"Development of enhanced separation techniques for oligonucleotides utilizing mixed-mode chromatography and 2D-LC\/UV\/MS analysis","volume":"48","author":"Haglof","year":"2025","journal-title":"J. Sep Sci."},{"key":"10.1016\/j.jpba.2026.117495_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464722","article-title":"In-line buffer exchange in the coupling of Protein A chromatography with weak cation exchange chromatography for the determination of charge variants of immunoglobulin G derived from chinese hamster ovary cell cultures","volume":"1718","author":"Wysor","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"19","key":"10.1016\/j.jpba.2026.117495_bib14","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/jssc.201400515","article-title":"Peak purity assessment in a triple-active fixed-dose combination drug product related substances method using a commercial two-dimensional liquid chromatography system","volume":"37","author":"Shackman","year":"2014","journal-title":"J. Sep Sci."},{"issue":"3","key":"10.1016\/j.jpba.2026.117495_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs-a review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117495_bib16","series-title":"Methods for Stability Testing of Pharmaceuticals","first-page":"75","article-title":"Forced degradation and long-term stability testing for oral drug products: a practical approach","author":"Zimmer","year":"2018"},{"key":"10.1016\/j.jpba.2026.117495_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114787","article-title":"Advancing forced degradation studies: design of experiments for enhanced structure-function relationship analysis in biotherapeutics","volume":"214","author":"Kronsbein","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2026.117495_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2015.10.016","article-title":"Forced degradation studies of biopharmaceuticals: selection of stress conditions","volume":"98","author":"Tamizi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.jpba.2026.117495_bib19","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.xphs.2023.09.003","article-title":"Pharmaceutical forced degradation (stress testing) endpoints: a scientific rationale and industry perspective","volume":"112","author":"Zelesky","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117495_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2013.07.013","article-title":"Forced degradation and impurity profiling: recent trends in analytical perspectives","volume":"86","author":"Jain","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2026.117495_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10337-017-3393-0","article-title":"Review on implementation of multivariate approach for forced degradation study and impurity profiling with regulatory considerations","volume":"81","author":"Patel","year":"2018","journal-title":"Chromatographia"},{"issue":"1","key":"10.1016\/j.jpba.2026.117495_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10337-023-04294-9","article-title":"Forced degradation of an anticancer drug apalutamide: impurity profiling and structure elucidation study","volume":"87","author":"Sapkal","year":"2024","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2026.117495_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115352","article-title":"Identification and enrichment of a UV-induced degradant of Anagrelide drug substance","volume":"229","author":"Li","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2026.117495_bib24","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR Exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.jpba.2026.117495_bib25","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jpba.2026.117495_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"24","key":"10.1016\/j.jpba.2026.117495_bib27","doi-asserted-by":"crossref","first-page":"12008","DOI":"10.1021\/ac502300q","article-title":"NMR flow tube for online NMR reaction monitoring","volume":"86","author":"Foley","year":"2014","journal-title":"Anal. Chem."},{"issue":"12","key":"10.1016\/j.jpba.2026.117495_bib28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/mrc.5035","article-title":"NMR spectroscopy goes mobile: Using NMR as process analytical technology at the fume hood","volume":"58","author":"Lee","year":"2020","journal-title":"Magn. Reson Chem."},{"issue":"8","key":"10.1016\/j.jpba.2026.117495_bib29","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1021\/acs.molpharmaceut.1c00261","article-title":"Kinetic modeling of API oxidation: (1) the AIBN\/HO\/CHOH radical \"soup\"","volume":"18","author":"Dana","year":"2021","journal-title":"Mol. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:15:31Z","timestamp":1777097731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0731708526001639"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117495","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategic characterization of active pharmaceutical ingredients co-eluting impurities: Identification, enrichment and structural elucidation of an oxidized impurity from mobocertinib drug substance","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117495"}}